Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Web Exclusives

Web Exclusives published on December 9, 2013 in Press Releases
Onco360 Expected to Rapidly Grow Revenues Over the Next Several Years
Web Exclusives published on January 4, 2011 in In the News
Adult survivors of childhood acute lymphoblastic leukemia (ALL) treated with dexamethasone may have greater risk for neurocognitive impairment and poor emotional regulation than patients treated with prednisone, and they exhibited symptoms of physical stress.
Web Exclusives published on January 4, 2011 in In the News
Almost half of the cancer patients in a recent study did not receive any thromboprophylaxis during hospitalization, even though cancer and its treatment increases the risk for deep-vein thrombosis (DVT) and pulmonary embolism (PE) and three professional organizations—the American College of Chest Physicians, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network—have issued guidelines recommending DVT prophylaxis.
Web Exclusives published on December 23, 2010 in Breast Cancer, In the News
SAN ANTONIO—A re-analysis of the Women’s Health Initiative (WHI)—which found an increased risk of breast cancer and heart disease in women taking hormone replacement therapy (HRT)—suggests that estrogen alone, without progesterone, may actually be protective against breast cancer. 
Web Exclusives published on December 23, 2010 in Breast Cancer, In the News
SAN ANTONIO—A rapidly growing, nationwide clinical trial matching service that is user-friendly for patients is enabling more patients to learn about and enroll in clinical trials, said Ellie Cohen, PhD, the program’s director. Cohen described the success of her program at the 33rd annual San Antonio Breast Cancer Symposium. 
Web Exclusives published on December 23, 2010 in Breast Cancer, In the News
SAN ANTONIO—In a trial involving women with stage II/III breast cancer (N = 3360), adding zoledronic acid (ZA) to standard adjuvant chemotherapy did not prolong overall survival (OS) or disease-free survival (DFS) after a median follow-up of 59 months, contrary to some previous reports.
Web Exclusives published on December 23, 2010 in Drug Therapies, In the News
SAN ANTONIO—For women with human epidermal growth factor receptor type 2 (HER2)-overexpressing breast cancer, preoperative treatment with agents that block HER2 leads to high rates of pathological complete response (pCR), according to the results of three studies presented at the 33rd annual San Antonio Breast Cancer Symposium. 
Web Exclusives published on December 23, 2010 in Supportive Care, In the News
ORLANDO—Patients often do not understand the terms clinicians use to describe their hematologic malignancies, such as myelodysplastic syndrome, which may lead to misunderstandings about their disease. 
Web Exclusives published on December 23, 2010 in In the News
ORLANDO—Low doses of alemtuzumab were effective in preventing graft-versus-host disease (GVHD) in leukemia patients receiving sibling and matched unrelated hematopoietic cell transplants. 
Web Exclusives published on December 10, 2010 in Prevention, In the News

ORLANDO—Breakthrough pain in cancer patients can be managed easily and effectively with fentanyl pectin nasal spray, according to new data.

Minocycline, given before the start of treatment with cetuximab and chemoradiotherapy, plus topical pimecrolimus as needed, can reduce the severity of cetuximab-induced skin toxicity in patients with non–small-cell lung cancer (NSCLC), according to researchers from The Netherlands.

Page 11 of 12
Results 101 - 110 of 115